Pharmacokinetics and pharmacokinetic interactions of orally administered oxfendazole and oxyclozanide tablet formulation to sheep. Issue 1 (3rd October 2022)

• Record Type: Journal Article
• Authors: Ozdemir Kutahya, Zeynep; Kandir, Sinan; Eser Faki, Hatice; Uney, Kamil; Tras, Bunyamin; Celik, Mehmet; Torun, Osman
• Is Part Of: Journal of veterinary pharmacology and therapeutics. Volume 46:Issue 1(2023)
• Page Start: 34
• Page End: 41
• Publication Date: 2022-10-03
• Subjects: interaction -- oral -- oxfendazole -- oxyclozanide -- pharmacokinetics -- sheep; Veterinary pharmacology -- Periodicals; Therapeutics -- Periodicals; 636.0895105
• DOI: 10.1111/jvp.13096
• Languages: English
• ISSNs: 0140-7783

Abstract

Abstract: The combination of oxfendazole and oxyclozanide is used to provide activity against fluke and gastrointestinal nematodes. This study aimed to determine both the pharmacokinetics of oxfendazole (7.5 mg/kg) and oxyclozanide (15 mg/kg) tablet formulation administered orally to sheep and whether there is a pharmacokinetic interaction between these two drugs. The study was conducted in a three‐period, crossover pharmacokinetic design and on six healthy Awassi sheep 1–3 years of age. The plasma concentrations of oxfendazole and its metabolites (fenbendazole and fenbendazole sulphone) and oxyclozanide were determined by high‐performance liquid chromatography using an ultraviolet detector. Compounds recovered in plasma when oxfendazole was administered alone or combined with oxyclozanide were oxfendazole, fenbendazole sulphone, and fenbendazole, respectively. When oxfendazole was administered alone and co‐administered with oxyclozanide, the AUCFBZ /AUCOFZ was 0.26 and 0.23, respectively, and the AUCFBZSO2 /AUCOFZ was 0.35 and 0.32, respectively. The volume of distribution (Vz/F) of oxfendazole was large in both groups. Oxyclozanide did not change the plasma disposition of oxfendazole. When the oxyclozanide tablet formulation was administered alone, the elimination half‐life (21.35 h) and the Vz/F (940.17 ml/kg) were long and large, respectively. The area under the curve (AUC) and the maximum plasma concentration of oxyclozanide were significantly larger and higher, respectively, in the oxyclozanide plus oxfendazole group (1146.61 h × μg/ml and 29.80 μg/ml) compared with the oxyclozanide group (491.44 h × μg/ml and 14.24 μg/ml) while a significant decrease in apparent Vz/F (940.17 vs 379.14 ml/kg) and total clearance (30.52 vs 13.08 ml/h/kg) was detected. In conclusion, co‐administration with oxfendazole causing an increase in the plasma profile of oxyclozanide may increase the antiparasitic activity of oxyclozanide.